FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.000304635 ordinary shares
Date of dealing	30/10/2020

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	573,474	0.44	958	0.00
(2) Derivatives (other than options)	858	0.00	13,183	0.01
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*1,975,513	*1.53	14,141	0.01

* Include the holding of 1,410,181 shares on borrow products

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	5	182.4
Purchase	95	182.4
Purchase	14	182.13
Purchase	40	186.25
Purchase	60	186.25
Purchase	50	181.06
Purchase	100	182.55
Purchase	585	182.48
Purchase	100	184.15
Purchase	100	182.87
Purchase	6	182.86
Purchase	100	185.93
Purchase	136	182.48
Purchase	1,171	182.48
Purchase	231	182.48
Sale	1	186.41
Sale	1	185.2
Sale	1	186.01
Sale	100	184.44
Sale	56	183.9
Sale	44	183.9
Sale	100	185.14
Sale	100	182.53
Sale	79	182.93
Sale	21	182.93
Sale	37	180.1
Sale	54	180.1
Sale	9	180.1
Sale	8	182.31
Sale	59	182.31
Sale	25	182.31
Sale	8	182.31
Sale	100	184.5
Sale	15	183.79
Sale	37	183.79
Sale	48	183.79
Sale	100	180.43
Sale	256	182.48
Sale	2,233	182.48
Total Purchases	2,793
Total Sales	3,492

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit USD

(Note 5)

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9) No

Date of disclosure	02/11/2020
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEDLLBBBFLXFBB